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Neutrophils engulf and kill invading microorganisms in a process called phago-
cytosis. Accompanying phagocytosis is the Respiratory Burst, a surge of activ-
ity by the enzyme NADPH oxidase. The enzyme transports electrons from the
cytosol to the phagosome, where it creats ROS that help to kill bacteria. This
electrogenic transport of electrons must be compensated for, so that the enzyme
can function continuously. Here we report for the first time the membrane po-
tential of individual phagocytosing neutrophils using a highly sensitive confo-
cal techinque.
Isolated human neutrophils were incubated with 10 mM di-8-ANEPPS for 15
minutes and allowed to adhere to glass coverslips. The cells were then washed
with Ringer’s solution and treated with either 60 nM PMA or opsonized zymo-
zan (OPZ). SEER consisted of ratioing two simultaneously acquired images of
fluorescence, excited at 488 nm and 545 nm and collected at emission ranges
470-560 nm and 570-700 nm respectively. Using this approach we were able
to detect a 26 % change in ratio from 50 to þ50 mV.
Neutrophils stimulated with 60 nM PMA depolarized 805 6 mV (n¼5) after
a delay of ~ 3 minutes. Addition of the NADPH oxidase inhibitor DPI repolar-
ized the membrane, confirming that the depolarization was due to NADPH ox-
idase activity. Neutrophils challenged with 2 mg/ml OPZ showed a depolariza-
tion spike of 865 11 mV (n¼5) that coincided with the onset of phagocytosis.
In both cases the depolarization lasted several minutes before subsiding spon-
taneously.
This study confirms that phagocytosis by human neutrophils is accompanied by
a large depolarization of their plasma membrane, a depolarization that can now
be monitored quantitatively and dynamically in individual cells.
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In this project, we have developed a model drug delivery system consisting of
non-ionic surfactant vesicles (niosomes) packaged within a biodegradable,
temperature and pH sensitive hydrogel network. We have characterized the be-
havior of individual niosomes when exposed to environments that mimic body
fluids. Diffusion and mass transfer characteristics of 5,6-Carboxyfluorescein,
a dye with similar physical properties as therapeutic drugs for cancer, is used
to determine release rate from the niosomes. The release rate can be controlled
to last from 24 hours to more than 144 hours depending on the conditions to
which individual niosomes are exposed. We used a cross-linked hydrogel (chi-
tosan) network into which the niosomes were embedded. The hydrogel pro-
vides another layer of control, gives a stable environment for the niosomes,
and enhances the release rate. The niosome-hydrogel system, which is a liquid
at room temperature, starts gelling once inside the body since it undergoes
a phase transition at 37C. Surface characteristics, such as the interaction be-
tween the niosomes and chitosan, Van der Waals forces and chemical bonding
are being measured by the Surface Force Apparatus (SFA) technique. One of
the systems that we are targeting with this study is intraperitonial cavities after
ovarian cancer is discovered and removed to increase the life span of patients.
Single administration rates have been tested and compared to local delivery via
an external catheter. We found that our system lasted longer than catheter ad-
ministration leading to less frequent administration and also resulted in reduced
toxicity. Our results will help in the development of a low cost and improved
method for drug delivery with application to intracavitary ovarian cancer treat-
ment and other cancer types.
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Localized drug delivery can provide better treatment for residual cancer tu-
mors. Our research proposes a ‘‘package within a package’’ drug delivery
system which results in an effective controlled release of the drug to the tar-
geted site and also reduces its toxic effects to other parts of the body. The
first part of the system is a non-ionic surfactant vesicle or niosome and the
second a biodegradable and temperature sensitive crosslinked hydrogel. The
vesicle is prepared by hydration of amphiphilic films with a PBS buffer so-
lution and a fluorescent marker, 5,6-carboxyfluorescein. We chose to encap-
sulate this particular marker to imitate and test the release rate of the chemo-
therapy drug from the vesicle interior. After hydration, the vesicles were
extruded to constrict their size distribution. Unentrapped dye was removed
using ultracentrifugation and gel exclusion chromatography. The dye encap-
sulated vesicles were placed in a semi-permeable cellulose membrane and
immersed in a solution of either PBS or Milli-Q water. The environment
in the PBS solution would closely mimic the vesicle’s behavior in the hydro-
gel and the water environment would closely follow the behavior near a re-
sidual cancer site, where the pH tends to be lower compared to blood. Dif-
fusion of the dye through the membrane was determined at different time
intervals by using fluorescence spectroscopy and its release rate was deter-
mined. The maker encapsulated niosomes will then be embedded into the
hydrogel network which will begin to degrade with time exposing the nio-
somes to a different pH that will cause them to rupture. The thermal sensi-
tive hydrogel is a polymer, chosen to be Chitosan. Chitosan is a biomaterial
obtained abundantly in nature. This system will then have antibodies to pro-
vide specificity. Using this methodology, we hope to provide a better treat-
ment technique for cancer patients.
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